id |
doaj-a11e66ba07da47ec857619b388733646
|
record_format |
Article
|
spelling |
doaj-a11e66ba07da47ec857619b3887336462020-11-25T01:00:12ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0191010.1371/journal.pone.0110098Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation.http://europepmc.org/articles/PMC4182882
|
collection |
DOAJ
|
language |
English
|
format |
Article
|
sources |
DOAJ
|
title |
Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation.
|
spellingShingle |
Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation.
PLoS ONE
|
title_short |
Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation.
|
title_full |
Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation.
|
title_fullStr |
Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation.
|
title_full_unstemmed |
Correction: High-Throughput Screening Identifies Idarubicin as a Preferential Inhibitor of Smooth Muscle versus Endothelial Cell Proliferation.
|
title_sort |
correction: high-throughput screening identifies idarubicin as a preferential inhibitor of smooth muscle versus endothelial cell proliferation.
|
publisher |
Public Library of Science (PLoS)
|
series |
PLoS ONE
|
issn |
1932-6203
|
publishDate |
2014-01-01
|
url |
http://europepmc.org/articles/PMC4182882
|
_version_ |
1725214598919880704
|